A study testing whether a GLP-1 medicine from Lilly, orforglipron, can ease joint pain.
What this means for you
- Who can join
- Adults 18+, have osteoarthritis (joint pain), BMI 27+.
- What you take
- orforglipron, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
- How long it lasts
- The full study runs about 2.7 years; your own time in it is usually shorter.
- What you get
- The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.
What this study is for
Primary condition: Osteoarthritis.
Full scientific study title: A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee.
Who can join
Adults 18+, have osteoarthritis (joint pain), BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Have a body mass index (BMI) of 27 kilograms per square meter (kg/m2) or higher at screening
- Have tried at least once to lose weight through diet but were unsuccessful
- Have osteoarthritis of the knee and at least one of the following conditions:
- Be over 50 years old
- Have morning knee stiffness that lasts about 30 minutes
Key exclusion criteria
- Have gained or lost more than 11 pounds within 90 days prior to screening
- Have had a surgery for obesity or plan to have one in the next 18 months
- Have an active knee infection
- Have type 1 diabetes, type 2 diabetes, or any other type of diabetes
- Have had a recent heart condition or New York Heart Association Functional Classification Class IV congestive heart failure
Where this study is enrolling
This trial has 26 sites across 17 states. Contact a site coordinator directly to start screening.
Arizona2 sites
- Arizona Research CenterPhoenix, Arizona602-863-6363
- AMR ClinicalTempe, Arizona602-910-3343
California2 sites
- Care Access - Huntington BeachHuntington Beach, California714-378-2440
- Care Access - Thousand OaksThousand Oaks, California805-778-5143
Colorado1 site
- Legacy Clinical TrialsColorado Springs, Colorado719-387-7572
Connecticut1 site
- Chase Medical Research, LLCWaterbury, Connecticut203-419-4420
Georgia2 sites
- Care Access - DecaturDecatur, Georgia678-470-4394
- North Georgia Clinical ResearchWoodstock, Georgia678-494-5735
Illinois1 site
- Northwestern UniversityChicago, Illinois312-503-2315
Kansas1 site
- AMR ClinicalNewton, Kansas316-804-7304
Massachusetts1 site
- MedVadis Research CorporationWaltham, Massachusetts617-744-1310
Missouri2 sites
- StudyMetrix ResearchCity of Saint Peters, Missouri636-387-5100
- AMR ClinicalKansas City, Missouri
New Jersey1 site
- Cardio Metabolic InstituteSomerset, New Jersey732-846-7000 x 108
North Carolina1 site
- Carolina Research CenterShelby, North Carolina704-600-6052
Pennsylvania1 site
- University Orthopedics CenterAltoona, Pennsylvania
South Dakota1 site
- Care Access - Rapid CityRapid City, South Dakota877-791-0656
Tennessee1 site
- AMR ClinicalKnoxville, Tennessee865-305-9100
Texas5 sites
- Mercy Family ClinicDallas, Texas281-944-3610
- Juno ResearchHouston, Texas713-779-5494
- Biopharma Informatic, LLCHouston, Texas281-944-3610
- Activian Clinical ResearchKingwood, Texas832-969-3401
- Advanced Rheumatology of Houston - WoodlandsThe Woodlands, Texas936-681-4882
Virginia2 sites
- Charlottesville Medical ResearchCharlottesville, Virginia434-817-2442
- Gershon Pain SpecialistsVirginia Beach, Virginia757-496-2050
Washington1 site
- Northwest Clinical Research CenterBellevue, Washington
Timeline
Started enrolling: 2025-09-15. Expected completion: 2028-05. Last updated on ClinicalTrials.gov: 2026-05-22.
Official source
We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.